Thermo Fisher Scientific Inc. $TMO Shares Bought by Boston Research & Management Inc.

Boston Research & Management Inc. lifted its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 17.6% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 10,954 shares of the medical research company’s stock after purchasing an additional 1,639 shares during the period. Boston Research & Management Inc.’s holdings in Thermo Fisher Scientific were worth $4,441,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Brighton Jones LLC lifted its stake in Thermo Fisher Scientific by 28.9% during the fourth quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company’s stock valued at $2,293,000 after buying an additional 988 shares in the last quarter. Revolve Wealth Partners LLC lifted its position in shares of Thermo Fisher Scientific by 4.2% in the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock valued at $255,000 after acquiring an additional 20 shares in the last quarter. Burney Co. boosted its stake in Thermo Fisher Scientific by 46.0% in the 1st quarter. Burney Co. now owns 1,237 shares of the medical research company’s stock worth $616,000 after purchasing an additional 390 shares during the period. Lifeworks Advisors LLC acquired a new stake in Thermo Fisher Scientific during the 1st quarter valued at $225,000. Finally, Cetera Investment Advisers lifted its holdings in shares of Thermo Fisher Scientific by 13.3% in the first quarter. Cetera Investment Advisers now owns 65,818 shares of the medical research company’s stock valued at $32,751,000 after purchasing an additional 7,703 shares in the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Analyst Ratings Changes

TMO has been the topic of a number of research analyst reports. JPMorgan Chase & Co. lifted their price target on Thermo Fisher Scientific from $600.00 to $650.00 and gave the company an “overweight” rating in a report on Thursday, October 9th. Wall Street Zen upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a report on Saturday, October 25th. Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of Thermo Fisher Scientific in a report on Thursday, October 23rd. Redburn Partners set a $580.00 target price on shares of Thermo Fisher Scientific in a research report on Wednesday, October 8th. Finally, Morgan Stanley boosted their price target on shares of Thermo Fisher Scientific from $560.00 to $656.00 and gave the company an “overweight” rating in a report on Tuesday, October 28th. Nineteen analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $601.65.

Insiders Place Their Bets

In other news, VP Lisa P. Britt sold 10,225 shares of the business’s stock in a transaction on Friday, November 7th. The shares were sold at an average price of $571.62, for a total value of $5,844,814.50. Following the completion of the sale, the vice president directly owned 14,145 shares in the company, valued at approximately $8,085,564.90. The trade was a 41.96% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Michel Lagarde sold 4,638 shares of the firm’s stock in a transaction on Thursday, November 13th. The shares were sold at an average price of $594.42, for a total transaction of $2,756,919.96. Following the completion of the transaction, the chief operating officer owned 23,480 shares in the company, valued at $13,956,981.60. The trade was a 16.49% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 41,845 shares of company stock worth $23,947,352 in the last three months. 0.33% of the stock is owned by insiders.

Thermo Fisher Scientific Price Performance

NYSE TMO opened at $587.47 on Friday. The company has a quick ratio of 1.11, a current ratio of 1.50 and a debt-to-equity ratio of 0.62. The stock has a market capitalization of $220.72 billion, a PE ratio of 33.94, a price-to-earnings-growth ratio of 3.27 and a beta of 0.82. Thermo Fisher Scientific Inc. has a 12-month low of $385.46 and a 12-month high of $610.97. The company has a 50 day moving average price of $537.07 and a two-hundred day moving average price of $473.46.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share for the quarter, beating analysts’ consensus estimates of $5.50 by $0.29. The business had revenue of $11.12 billion for the quarter, compared to the consensus estimate of $10.90 billion. Thermo Fisher Scientific had a net margin of 15.02% and a return on equity of 16.97%. Thermo Fisher Scientific’s revenue for the quarter was up 4.9% on a year-over-year basis. During the same quarter last year, the firm earned $5.28 EPS. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. As a group, equities analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, January 15th. Stockholders of record on Monday, December 15th will be issued a dividend of $0.43 per share. The ex-dividend date of this dividend is Monday, December 15th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio is currently 9.94%.

Thermo Fisher Scientific announced that its board has initiated a share buyback plan on Thursday, November 6th that permits the company to buyback $5.00 billion in shares. This buyback authorization permits the medical research company to purchase up to 2.4% of its stock through open market purchases. Stock buyback plans are usually a sign that the company’s board of directors believes its shares are undervalued.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.